A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

NCT03737851 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis (MS)

Interventions

DRUG: elezanumab
DRUG: placebo

Sponsor

AbbVie